At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Induction Carboplatin and Docetaxel Followed by Radiotherapy Then Consolidation Chemotherapy With Carboplatin and Docetaxel in Stage III, IV and Recurrent Endometrial Cancer
In Brief
A Phase 2 clinical trial evaluating carboplatin, docetaxel, and 1 other intervention for Endometrial Cancer. Completed, enrolled 41 participants across 2 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving carboplatin and docetaxel followed by radiation therapy works in treating patients with stage III, stage IV, or recurrent endometrial cancer.
Study Details
Timeline
Interventions
Dose = Area-under-the-curve 6 on Day 1 every 3 weeks for 3 cycles.
75 mg/m\^2 on Day 1 of each course
Weekly, 5 days/week over 6-7 weeks (tailored 4500 cGy)